相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Therapeutic options for difficult-to-treat Acinetobacter baumanniiinfections: a 2020 perspective
Matteo Bassetti et al.
EXPERT OPINION ON PHARMACOTHERAPY (2021)
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti et al.
LANCET INFECTIOUS DISEASES (2021)
Genome sequencing and molecular characterisation of XDR Acinetobacter baumannii reveal complexities in resistance: Novel combination of sulbactam-durlobactam holds promise for therapeutic intervention
Aniket Naha et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2021)
A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects
John O'Donnell et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists
Jacinda C. Abdul-Mutakabbir et al.
INFECTIOUS DISEASES AND THERAPY (2021)
In vitro activity of sulbactam/durlobactam against extensively drug-resistant Acinetobacter baumannii isolates belonging to South American major clones
Carolina S. Nodari et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)
In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally from 2016-2017
Sarah M. McLeod et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
Olexiy Sagan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects
Jason D. Lickliter et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China
Qiwen Yang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii
Harald Seifert et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative Treatment Strategies of Acinetobacter baumannii
Corneliu Ovidiu Vrancianu et al.
MICROORGANISMS (2020)
New beta-Lactam-beta-Lactamase Inhibitor Combinations
Dafna Yahav et al.
CLINICAL MICROBIOLOGY REVIEWS (2020)
International Consensus Guidelines for the Optimal Use of the Polymyxins Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)
Brian T. Tsuji et al.
PHARMACOTHERAPY (2019)
Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent
Melissa D. Barnes et al.
MBIO (2019)
β-Lactamases and β-Lactamase Inhibitors in the 21st Century
Catherine L. Tooke et al.
JOURNAL OF MOLECULAR BIOLOGY (2019)
Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects
John O'Donnell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections
Maddalena Giannella et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Uncovering the mechanisms of Acinetobacter baumannii virulence
Christian M. Harding et al.
NATURE REVIEWS MICROBIOLOGY (2018)
Acinetobacter baumannii OmpA Is a Selective Antibiotic Permeant Porin
Ramkumar Iyer et al.
ACS INFECTIOUS DISEASES (2018)
Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents
Sameer S. Kadri et al.
CLINICAL INFECTIOUS DISEASES (2018)
Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam - epidemiology, laboratory detection and treatment implications
Norelle Sherry et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2018)
Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities
Muhammad Asif et al.
INFECTION AND DRUG RESISTANCE (2018)
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Simon Portsmouth et al.
LANCET INFECTIOUS DISEASES (2018)
Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii
Sarah M. McLeod et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial A Randomized Clinical Trial
Joseph Solomkin et al.
JAMA SURGERY (2017)
Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514
Adam B. Shapiro et al.
ACS INFECTIOUS DISEASES (2017)
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
Thomas F. Durand-Reville et al.
NATURE MICROBIOLOGY (2017)
Combatting antimicrobial resistance globally
Rebecca Sugden et al.
Nature Microbiology (2016)
Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections
J. Alexander Viehman et al.
DRUGS (2014)
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
A. -P. Magiorakos et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia
D Panidis et al.
CHEST (2005)
分享论文
